Trial · NCT02948842
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects With Complication After Treatment | Treatment Group | 0 | Participants | ||
| Number of Patients Needing Further Intervention for Treatment of Urethral Stricture | Treatment Group | 3 | Participants | ||
| Number of Subjects With Recurrence of Urethral Stricture | Treatment Group | 0 | Participants | ||
| Change From Baseline and 6 Weeks: American Urology Association Questionnaire Scores | Treatment Group | -11.5 | Standard Deviation 3.5 | scores on a scale | |
| Change From Baseline and 6 Months: American Urology Association Questionnaire Scores | Treatment Group | -2.5 | Standard Deviation 14.8 | scores on a scale | |
| Change From Baseline and 9 Months: American Urology Association Questionnaire Scores | Treatment Group | -17 | scores on a scale | ||
| Change From Baseline and 12 Months: American Urology Association Questionnaire Scores | Treatment Group | -19 | scores on a scale | ||
| Change From Baseline and 2 Years: American Urology Association Questionnaire Scores | Treatment Group | -24 | scores on a scale | ||
| Time to Additional Intervention for Urethral Stricture | Treatment Group | 6 | Full Range 1 to 18 | months | |
| Change From Baseline and 6 Weeks: Obstructive Voiding Dysfunction (Uroflow) | Treatment Group | 1.5 | Standard Deviation 6.4 | mL/s | |
| Change From Baseline and 6 Months: Obstructive Voiding Dysfunction (Uroflow) | Treatment Group | -5.5 | Standard Deviation 7.8 | mL/s | |
| Change From Baseline and 9 Months: Obstructive Voiding Dysfunction (Uroflow) | Treatment Group | 3.6 | mL/s | ||
| Change From Baseline and 12 Months: Obstructive Voiding Dysfunction (Uroflow) | Treatment Group | 5.8 | mL/s | ||
| Change From Baseline and 18 Months: Obstructive Voiding Dysfunction (Uroflow) | Treatment Group | 19 | mL/s | ||
| Change From Baseline and 2 Years: Obstructive Voiding Dysfunction (Uroflow) | Treatment Group | 9.2 | mL/s | ||
| Change From Baseline and 6 Weeks: Obstructive Voiding Dysfunction (Post-void Residual Measurements) | Treatment Group | -41.5 | Standard Deviation 14.8 | mL | |
| Change From Baseline and 6 Months: Obstructive Voiding Dysfunction (Post-void Residual Measurements) | Treatment Group | 175.5 | Standard Deviation 224.1 | mL | |
| Change From Baseline and 9 Months: Obstructive Voiding Dysfunction (Post-void Residual Measurements) | Treatment Group | 125 | mL | ||
| Change From Baseline and 12 Months: Obstructive Voiding Dysfunction (Post-void Residual Measurements) | Treatment Group | 46 | mL | ||
| Change From Baseline and 18 Months: Obstructive Voiding Dysfunction (Post-void Residual Measurements) | Treatment Group | -48 | mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02948842/results